Voyager Technologies (VOYG) has secured a contract from the Center for the Advancement of Science in Space to manage Symphony Biosciences' biopolymer cancer implant experiment aboard the International Space Station, the company said Tuesday.

Financial details weren't disclosed.

Under the contract, Voyager is expected to adapt the experiment hardware for station equipment, support NASA safety reviews, manage launch integration and on-orbit operations, and help test SymphNode, a device designed to restore immune response by recruiting and activating T cells to fight cancer.

Voyager will return the experiment samples and data after the study and provide post-flight and close-out reporting.

Price: 30.93, Change: +0.73, Percent Change: +2.41